In this milestone 20th episode of The Conversational Flow, hosts Adam and Brian dive into impactful developments across oncology, regulatory science, and bioanalytical innovation. The episode highlig4 hts a major Keytruda study showing the first significant improvement in head and neck squamous cell carcinoma outcomes in over two decades, the FDA’s pilot integration of generative AI in scientific review processes, and Sanofi’s acquisition of AI-developed bispecific antibodies for autoimmune diseases. The conversation rounds out with thoughtful discussion on data harmonization across multicenter flow cytometry studies and updates on KCAS’s scientific contributions at CYTO and regional events.

“The Conversational Flow” an official podcast of KCAS Bio, and focuses on the more niche topic of Flow Cytometry and its role within the greater pharmaceutical, biopharmaceutical and bioanalytical industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Flow Cytometry experts as they chat over coffee and discuss what they’ve learned about the world of Flow Cytometry the past couple of weeks. “The Conversational Flow” is brought to you by KCAS Bio.

KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.